177 Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38170913.
- Also identified by DOI 10.1097/RLU.0000000000005010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report a 65-year-old man with metastatic castration-resistant prostate cancer who was treated with 2 cycles of 177 Lu-PSMA-617 therapy. PET/CT imaging of 68 Ga-PSMA-11 revealed a complete metabolic response (PERCIST1.0) after therapy. The prostate-specific antigen concentration drastically decreased (97.7% down).
Medical subject headings
- Prostate-Specific Antigen
- Prostatic Neoplasms, Castration-Resistant